$XAIR
Beyond Air, Inc. Stock $xair

$xair Overview Financials Valuation SEC Filings Company Website

2023 Q2 Form 10-K Financial Statement

#000149315223022150 Filed on June 22, 2023

Income Statement

Concept	2023 Q2	2023 Q1	2023
Revenue	$59.00K	$0.00
YoY Change
Cost Of Revenue	$303.0K	$310.0K	$555.0K
YoY Change
Gross Profit	-$244.0K	-$310.0K	-$555.0K
YoY Change
Gross Profit Margin	-413.56%
Selling, General & Admin	$10.94M	$9.550M	$34.69M
YoY Change	33.14%	53.54%	88.45%
% of Gross Profit
Research & Development	$4.695M	$4.130M	$16.81M
YoY Change	45.54%	11.29%	42.43%
% of Gross Profit
Depreciation & Amortization	$361.0K	$246.0K	$839.0K
YoY Change	198.35%	89.23%	138.35%
% of Gross Profit
Operating Expenses	$15.63M	$13.67M	$51.50M
YoY Change	36.63%	37.65%	70.49%
Operating Profit	-$15.88M	-$13.98M	-$52.06M
YoY Change	38.77%		27.88%
Interest Expense	$158.0K	$770.0K	$30.00K
YoY Change	229.17%	-242.59%	-103.28%
% of Operating Profit
Other Income/Expense, Net	$820.0K	-$320.0K	-$7.342M
YoY Change	-481.4%	-32100.0%	119.16%
Pretax Income	-$15.06M	-$21.15M	-$59.40M
YoY Change	29.17%	2.36%	34.82%
Income Tax		$0.00
% Of Pretax Income
Net Earnings	-$14.10M	-$20.17M	-$55.82M
YoY Change	28.91%	0.83%	29.27%
Net Earnings / Revenue	-23889.83%
Basic Earnings Per Share	-$0.45		-$1.86
Diluted Earnings Per Share	-$0.45	-$0.67	-$1.86
COMMON SHARES
Basic Shares Outstanding	31.68M shares	30.09M shares	29.97M shares
Diluted Shares Outstanding	31.38M shares		29.97M shares

Balance Sheet

Concept	2023 Q2	2023 Q1	2023
SHORT-TERM ASSETS
Cash & Short-Term Investments	$56.99M	$45.88M	$45.88M
YoY Change	-21.69%	-42.82%	-42.82%
Cash & Equivalents	$31.35M	$29.16M	$29.16M
Short-Term Investments	$25.64M	$16.72M	$16.72M
Other Short-Term Assets	$4.350M	$11.75M	$11.75M
YoY Change	-62.13%	-2.9%	-0.01%
Inventory	$1.339M	$1.129M	$1.129M
Prepaid Expenses
Receivables	$44.00K
Other Receivables	$638.0K
Total Short-Term Assets	$63.36M	$59.41M	$59.41M
YoY Change	-25.83%	-36.08%	-36.08%
LONG-TERM ASSETS
Property, Plant & Equipment	$5.474M	$5.003M	$7.496M
YoY Change	156.75%	150.78%	78.01%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$226.0K	$212.0K	$211.0K
YoY Change	8.13%	2.42%	2.43%
Total Long-Term Assets	$9.681M	$9.339M	$9.339M
YoY Change	49.4%	49.33%	49.33%
TOTAL ASSETS
Total Short-Term Assets	$63.36M	$59.41M	$59.41M
Total Long-Term Assets	$9.681M	$9.339M	$9.339M
Total Assets	$73.04M	$68.75M	$68.75M
YoY Change	-20.52%	-30.7%	-30.7%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$1.738M	$2.016M	$2.016M
YoY Change	67.44%	78.57%	78.57%
Accrued Expenses	$9.401M	$16.61M	$16.99M
YoY Change	14.46%	98.39%	96.29%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$695.0K	$695.0K
YoY Change	-100.0%	-25.03%	-25.03%
Long-Term Debt Due	$495.0K	$80.00K	$80.00K
YoY Change
Total Short-Term Liabilities	$12.02M	$19.78M	$19.78M
YoY Change	18.27%	84.65%	84.65%
LONG-TERM LIABILITIES
Long-Term Debt	$13.75M	$120.0K	$120.0K
YoY Change	6774.5%	-40.0%	-40.0%
Other Long-Term Liabilities	$4.500M	$6.821M	$6.821M
YoY Change	-55.85%	-32.32%	-32.32%
Total Long-Term Liabilities	$4.500M	$6.941M	$6.941M
YoY Change	-56.7%	-32.47%	-32.47%
TOTAL LIABILITIES
Total Short-Term Liabilities	$12.02M	$19.78M	$19.78M
Total Long-Term Liabilities	$4.500M	$6.941M	$6.941M
Total Liabilities	$33.90M	$26.72M	$30.83M
YoY Change	64.94%	27.3%	16.38%
SHAREHOLDERS EQUITY
Retained Earnings	-$193.6M	-$179.5M
YoY Change	43.83%	45.18%
Common Stock	$3.000K	$3.000K
YoY Change	0.0%	0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)	$25.00K	$25.00K
YoY Change	0.0%	0.0%
Treasury Stock Shares
Shareholders Equity	$35.46M	$37.92M	$37.92M
YoY Change
Total Liabilities & Shareholders Equity	$73.04M	$68.75M	$68.75M
YoY Change	-20.52%	-30.7%	-30.7%

Cashflow Statement

Concept	2023 Q2	2023 Q1	2023
OPERATING ACTIVITIES
Net Income	-$14.10M	-$20.17M	-$55.82M
YoY Change	28.91%	0.83%	29.27%
Depreciation, Depletion And Amortization	$361.0K	$246.0K	$839.0K
YoY Change	198.35%	89.23%	138.35%
Cash From Operating Activities	-$17.20M	-$8.440M	-$33.00M
YoY Change	152.94%	6.85%	42.65%
INVESTING ACTIVITIES
Capital Expenditures	$795.0K	$2.022M	$3.877M
YoY Change	208.14%	-691.23%	-380.94%
Acquisitions
YoY Change
Other Investing Activities	-$8.858M	$10.88M	-$16.71M
YoY Change	147533.33%	362633.33%	23771.43%
Cash From Investing Activities	-$9.653M	$8.860M	-$20.59M
YoY Change	3556.44%	-2713.57%	1319.79%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net			$0.00
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	$21.57M	3.409M	$2.696M
YoY Change	-4123.69%	-39.86%	-96.61%
NET CHANGE
Cash From Operating Activities	-$17.20M	-8.440M	-$33.00M
Cash From Investing Activities	-$9.653M	8.860M	-$20.59M
Cash From Financing Activities	$21.57M	3.409M	$2.696M
Net Change In Cash	-$5.199M	3.829M	-$50.94M
YoY Change	-30.38%	-248.99%	-192.85%
FREE CASH FLOW
Cash From Operating Activities	-$17.20M	-$8.440M	-$33.00M
Capital Expenditures	$795.0K	$2.022M	$3.877M
Free Cash Flow	-$18.00M	-$10.46M	-$36.88M
YoY Change	154.96%	38.44%	69.52%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2023	dei	Entity Central Index Key EntityCentralIndexKey	0001641631
CY2023	dei	Amendment Flag AmendmentFlag	false
CY2023	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2022Q1	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent		usd
CY2023Q1	us-gaap	Preferred Stock Value PreferredStockValue		usd
CY2022Q1	us-gaap	Preferred Stock Value PreferredStockValue		usd
CY2023	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax		usd
CY2022	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax		usd
CY2022	us-gaap	Cost Of Revenue CostOfRevenue		usd
CY2022	us-gaap	Gross Profit GrossProfit		usd
CY2023	XAIR	Milestone Expenses Incurred Upon Regulatory Approval MilestoneExpensesIncurredUponRegulatoryApproval		usd
CY2022	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation		usd
CY2022	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised		usd
CY2022	us-gaap	Stock Issued During Period Value Restricted Stock Award Gross StockIssuedDuringPeriodValueRestrictedStockAwardGross		usd
CY2023	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised		usd
CY2023	us-gaap	Stock Issued During Period Value Restricted Stock Award Gross StockIssuedDuringPeriodValueRestrictedStockAwardGross		usd
CY2023	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts		usd
CY2022	us-gaap	Marketable Securities Unrealized Gain Loss MarketableSecuritiesUnrealizedGainLoss		usd
CY2023	XAIR	Foreign Currency Adjustments ForeignCurrencyAdjustments		usd
CY2022	us-gaap	Asset Impairment Charges AssetImpairmentCharges		usd
CY2022	us-gaap	Provision For Other Losses ProvisionForOtherLosses		usd
CY2022	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories		usd
CY2022	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability		usd
CY2023	XAIR	Increase Decrease Accrued Liabilities IncreaseDecreaseAccruedLiabilities		usd
CY2022	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities		usd
CY2022	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities		usd
CY2023	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises		usd
CY2023	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised		usd
CY2023	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock		usd
CY2023	XAIR	Proceeds From Issuance Of Common Stock In Connection With Purchase Agreement ProceedsFromIssuanceOfCommonStockInConnectionWithPurchaseAgreement		usd
CY2023	XAIR	Proceeds From Net Recovery Of Shortswing Profits From Related Parties ProceedsFromNetRecoveryOfShortswingProfitsFromRelatedParties		usd
CY2023	us-gaap	Proceeds From Bank Debt ProceedsFromBankDebt		usd
CY2023	XAIR	Accelerated Amortization Of Debt Discount Costs On Retirement Of Debt AcceleratedAmortizationOfDebtDiscountCostsOnRetirementOfDebt		usd
CY2023	XAIR	Increase Licensed Right To Use Technology From Nitricgen Agreement IncreaseLicensedRightToUseTechnologyFromNitricgenAgreement		usd
CY2023	XAIR	Nitricgen Accrued Liability Due To Fda Approval NitricgenAccruedLiabilityDueToFdaApproval		usd
CY2023	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet		usd
CY2022	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet		usd
CY2022Q1	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent		usd
CY2023Q1	us-gaap	Property Plant And Equipment Useful Life Description Of Term Extensible Enumeration PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration	http://fasb.org/us-gaap/2023#LeaseholdImprovementsMember
CY2023	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises		usd
CY2023Q1	XAIR	Nitricgen Agreement NitricgenAgreement		usd
CY2022Q1	XAIR	Deferred Tax Assets Tax Deferred Expense Compensation And Depreciation DeferredTaxAssetsTaxDeferredExpenseCompensationAndDepreciation		usd
CY2023Q1	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet		usd
CY2022Q1	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet		usd
CY2023	dei	Document Type DocumentType	10-K
CY2023	dei	Document Annual Report DocumentAnnualReport	true
CY2023	dei	Document Period End Date DocumentPeriodEndDate	2023-03-31
CY2023	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--03-31
CY2023	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2023	dei	Document Transition Report DocumentTransitionReport	false
CY2023	dei	Entity File Number EntityFileNumber	001-38892
CY2023	dei	Entity Registrant Name EntityRegistrantName	BEYOND AIR, INC.
CY2023	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2023	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	47-3812456
CY2023	dei	Entity Address Address Line1 EntityAddressAddressLine1	900 Stewart Avenue
CY2023	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 301
CY2023	dei	Entity Address City Or Town EntityAddressCityOrTown	Garden City
CY2023	dei	Entity Address State Or Province EntityAddressStateOrProvince	NY
CY2023	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	11530
CY2023	dei	City Area Code CityAreaCode	516
CY2023	dei	Local Phone Number LocalPhoneNumber	665-8200
CY2023	dei	Security12b Title Security12bTitle	Common Stock, par value $0.0001 per share
CY2023	dei	Trading Symbol TradingSymbol	XAIR
CY2023	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2023	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2023	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2023	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2023	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2023	dei	Entity Small Business EntitySmallBusiness	true
CY2023	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2023	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	false
CY2023	dei	Document Fin Stmt Error Correction Flag DocumentFinStmtErrorCorrectionFlag	false
CY2023	dei	Entity Shell Company EntityShellCompany	false
CY2022Q3	dei	Entity Public Float EntityPublicFloat	201200000	usd
CY2023Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	31675521	shares
CY2023	dei	Auditor Name AuditorName	Marcum LLP
CY2023	dei	Auditor Firm AuditorFirmId	688
CY2022	dei	Auditor Name AuditorName	Friedman LLP
CY2022	dei	Auditor Firm AuditorFirmId	711
CY2023	dei	Auditor Location AuditorLocation	East Hanover, New Jersey
CY2022	dei	Auditor Location AuditorLocation	East Hanover, New Jersey
CY2023Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	29158000	usd
CY2022Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	80242000	usd
CY2023Q1	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	16724000	usd
CY2023Q1	us-gaap	Restricted Cash Current RestrictedCashCurrent	10129000	usd
CY2022Q1	us-gaap	Restricted Cash Current RestrictedCashCurrent	9988000	usd
CY2023Q1	us-gaap	Inventory Net InventoryNet	1129000	usd
CY2022Q1	us-gaap	Inventory Net InventoryNet	350000	usd
CY2023Q1	us-gaap	Receivables Net Current ReceivablesNetCurrent	420000	usd
CY2022Q1	us-gaap	Receivables Net Current ReceivablesNetCurrent	322000	usd
CY2023Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1850000	usd
CY2022Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	2044000	usd
CY2023Q1	us-gaap	Assets Current AssetsCurrent	59410000	usd
CY2022Q1	us-gaap	Assets Current AssetsCurrent	92945000	usd
CY2023Q1	XAIR	Licensed Right To Use Technology LicensedRightToUseTechnology	1632000	usd
CY2022Q1	XAIR	Licensed Right To Use Technology LicensedRightToUseTechnology	1837000	usd
CY2023Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	2493000	usd
CY2022Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	2216000	usd
CY2023Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	5003000	usd
CY2022Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1995000	usd
CY2023Q1	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	212000	usd
CY2022Q1	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	207000	usd
CY2023Q1	us-gaap	Assets Assets	68749000	usd
CY2022Q1	us-gaap	Assets Assets	99199000	usd
CY2023Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	2016000	usd
CY2022Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	1129000	usd
CY2023Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	16613000	usd
CY2022Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	8374000	usd
CY2023Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	376000	usd
CY2022Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	281000	usd
CY2023Q1	us-gaap	Loans Payable Current LoansPayableCurrent	775000	usd
CY2022Q1	us-gaap	Loans Payable Current LoansPayableCurrent	927000	usd
CY2023Q1	us-gaap	Liabilities Current LiabilitiesCurrent	19780000	usd
CY2022Q1	us-gaap	Liabilities Current LiabilitiesCurrent	10712000	usd
CY2023Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	2321000	usd
CY2022Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	2079000	usd
CY2023Q1	us-gaap	Long Term Loans Payable LongTermLoansPayable	120000	usd
CY2022Q1	us-gaap	Long Term Loans Payable LongTermLoansPayable	200000	usd
CY2023Q1	us-gaap	Other Long Term Debt OtherLongTermDebt	4500000	usd
CY2022Q1	us-gaap	Other Long Term Debt OtherLongTermDebt	8000000	usd
CY2023Q1	us-gaap	Liabilities Liabilities	26721000	usd
CY2022Q1	us-gaap	Liabilities Liabilities	20990000	usd
CY2023Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2022Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2023Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2022Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2023Q1	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2023Q1	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2022Q1	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2022Q1	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2023Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2022Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2023Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2022Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2023Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	30738585	shares
CY2023Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	30738585	shares
CY2022Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	29886173	shares
CY2022Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	29886173	shares
CY2023Q1	us-gaap	Common Stock Value CommonStockValue	3000	usd
CY2022Q1	us-gaap	Common Stock Value CommonStockValue	3000	usd
CY2023Q1	us-gaap	Treasury Stock Value TreasuryStockValue	25000	usd
CY2022Q1	us-gaap	Treasury Stock Value TreasuryStockValue	25000	usd
CY2023Q1	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	217339000	usd
CY2022Q1	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	196269000	usd
CY2023Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-179455000	usd
CY2022Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-123639000	usd
CY2023Q1	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	53000	usd
CY2022Q1	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	96000	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	37915000	usd
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	72704000	usd
CY2023Q1	us-gaap	Minority Interest MinorityInterest	4113000	usd
CY2022Q1	us-gaap	Minority Interest MinorityInterest	5505000	usd
CY2023Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	42028000	usd
CY2022Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	78209000	usd
CY2023Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	68749000	usd
CY2022Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	99199000	usd
CY2023	us-gaap	Cost Of Revenue CostOfRevenue	555000	usd
CY2023	us-gaap	Gross Profit GrossProfit	-555000	usd
CY2023	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	16810000	usd
CY2022	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	11802000	usd
CY2023	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	34694000	usd
CY2022	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	18408000	usd
CY2022	XAIR	Milestone Expenses Incurred Upon Regulatory Approval MilestoneExpensesIncurredUponRegulatoryApproval	10500000	usd
CY2023	us-gaap	Operating Expenses OperatingExpenses	51504000	usd
CY2022	us-gaap	Operating Expenses OperatingExpenses	40710000	usd
CY2023	us-gaap	Operating Income Loss OperatingIncomeLoss	-52059000	usd
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-40710000	usd
CY2023	XAIR	Estimated Liability For Contingent Loss EstimatedLiabilityForContingentLoss	-7863000	usd
CY2022	XAIR	Estimated Liability For Contingent Loss EstimatedLiabilityForContingentLoss	-2435000	usd
CY2023	us-gaap	Dividend Income Operating DividendIncomeOperating	656000	usd
CY2022	us-gaap	Dividend Income Operating DividendIncomeOperating	4000	usd
CY2023	us-gaap	Interest Expense InterestExpense	30000	usd
CY2022	us-gaap	Interest Expense InterestExpense	775000	usd
CY2023	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-105000	usd
CY2022	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-144000	usd
CY2023	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-7342000	usd
CY2022	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-3350000	usd
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-59401000	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-44060000	usd
CY2023	us-gaap	Profit Loss ProfitLoss	-59401000	usd
CY2022	us-gaap	Profit Loss ProfitLoss	-44060000	usd
CY2023	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-3585000	usd
CY2022	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-882000	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-55816000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-43177000	usd
CY2023	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-43000	usd
CY2022	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	96000	usd
CY2023	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	-55859000	usd
CY2022	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	-43081000	usd
CY2023	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.86
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.68
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	29973639	shares
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	25668230	shares
CY2021Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	30464000	usd
CY2022	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	36489000	usd
CY2022	us-gaap	Stock Issued During Period Value Acquisitions StockIssuedDuringPeriodValueAcquisitions	11138000	usd
CY2022	XAIR	Stock Issued During Exercise Of Warrants Value StockIssuedDuringExerciseOfWarrantsValue	251000	usd
CY2022	us-gaap	Stock Granted During Period Value Sharebased Compensation Gross StockGrantedDuringPeriodValueSharebasedCompensationGross	5966000	usd
CY2022	us-gaap	Adjustments To Additional Paid In Capital Stock Issued Issuance Costs AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts	30000000	usd
CY2022	XAIR	Net Recovery Of Short Swing Profits NetRecoveryOfShortSwingProfits	33000	usd
CY2022	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	7831000	usd
CY2022	us-gaap	Other Comprehensive Income Loss Before Tax OtherComprehensiveIncomeLossBeforeTax	96000	usd
CY2022	us-gaap	Profit Loss ProfitLoss	-44060000	usd
CY2022Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	78209000	usd
CY2022Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	78209000	usd
CY2022Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	78209000	usd
CY2023	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	3705000	usd
CY2023	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	19559000	usd
CY2023	us-gaap	Other Comprehensive Income Loss Before Tax OtherComprehensiveIncomeLossBeforeTax	-43000	usd
CY2023Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	42028000	usd
CY2023Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	42028000	usd
CY2023	us-gaap	Profit Loss ProfitLoss	-59401000	usd
CY2022	us-gaap	Profit Loss ProfitLoss	-44060000	usd
CY2023	us-gaap	Depreciation And Amortization DepreciationAndAmortization	634000	usd
CY2022	us-gaap	Depreciation And Amortization DepreciationAndAmortization	314000	usd
CY2023	us-gaap	Share Based Compensation ShareBasedCompensation	19558000	usd
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	7831000	usd
CY2022	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	528000	usd
CY2023	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	205000	usd
CY2022	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	38000	usd
CY2023	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	331000	usd
CY2022	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	236000	usd
CY2023	us-gaap	Marketable Securities Unrealized Gain Loss MarketableSecuritiesUnrealizedGainLoss	12000	usd
CY2022	XAIR	Foreign Currency Adjustments ForeignCurrencyAdjustments	144000	usd
CY2023	us-gaap	Asset Impairment Charges AssetImpairmentCharges	235000	usd
CY2023	us-gaap	Provision For Other Losses ProvisionForOtherLosses	49000	usd
CY2023	us-gaap	Increase Decrease In Receivables IncreaseDecreaseInReceivables	98000	usd
CY2022	us-gaap	Increase Decrease In Receivables IncreaseDecreaseInReceivables	-103000	usd
CY2023	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	781000	usd
CY2023	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-918000	usd
CY2022	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	816000	usd
CY2023	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	838000	usd
CY2022	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-327000	usd
CY2023	us-gaap	Increase Decrease In Other Accrued Liabilities IncreaseDecreaseInOtherAccruedLiabilities	4791000	usd
CY2022	us-gaap	Increase Decrease In Other Accrued Liabilities IncreaseDecreaseInOtherAccruedLiabilities	4874000	usd
CY2023	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-275000	usd
CY2022	XAIR	Increase Decrease Accrued Liabilities IncreaseDecreaseAccruedLiabilities	8000000	usd
CY2023	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-33009000	usd
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-23134000	usd
CY2023	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	35656000	usd
CY2023	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	18945000	usd
CY2023	XAIR	Payments To Security Deposits Made On Operating Leases PaymentsToSecurityDepositsMadeOnOperatingLeases	1000	usd
CY2022	XAIR	Payments To Security Deposits Made On Operating Leases PaymentsToSecurityDepositsMadeOnOperatingLeases	-69000	usd
CY2023	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	3877000	usd
CY2022	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	1380000	usd
CY2023	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-20587000	usd
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-1450000	usd
CY2023	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement	3705000	usd
CY2022	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement	36489000	usd
CY2022	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	5966000	usd
CY2022	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	251000	usd
CY2022	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	25200000	usd
CY2022	XAIR	Proceeds From Issuance Of Common Stock In Connection With Purchase Agreement ProceedsFromIssuanceOfCommonStockInConnectionWithPurchaseAgreement	11138000	usd
CY2022	XAIR	Proceeds From Net Recovery Of Shortswing Profits From Related Parties ProceedsFromNetRecoveryOfShortswingProfitsFromRelatedParties	33000	usd
CY2022	us-gaap	Proceeds From Bank Debt ProceedsFromBankDebt	1029000	usd
CY2023	us-gaap	Repayments Of Bank Debt RepaymentsOfBankDebt	1009000	usd
CY2022	us-gaap	Repayments Of Bank Debt RepaymentsOfBankDebt	658000	usd
CY2023	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	2696000	usd
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	79450000	usd
CY2023	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	-43000	usd
CY2022	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	96000	usd
CY2023	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-50944000	usd
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	54962000	usd
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	90230000	usd
CY2021Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	35268000	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	39287000	usd
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	90230000	usd
CY2023	XAIR	Rightofuse Assets RightofuseAssets	609000	usd
CY2022	XAIR	Rightofuse Assets RightofuseAssets	693000	usd
CY2023	XAIR	Operating Lease Liabilities OperatingLeaseLiabilities	609000	usd
CY2022	XAIR	Operating Lease Liabilities OperatingLeaseLiabilities	693000	usd
CY2022	XAIR	Accelerated Amortization Of Debt Discount Costs On Retirement Of Debt AcceleratedAmortizationOfDebtDiscountCostsOnRetirementOfDebt	390000	usd
CY2022	XAIR	Increase Licensed Right To Use Technology From Nitricgen Agreement IncreaseLicensedRightToUseTechnologyFromNitricgenAgreement	1500000	usd
CY2022	XAIR	Nitricgen Accrued Liability Due To Fda Approval NitricgenAccruedLiabilityDueToFdaApproval	1500000	usd
CY2023	us-gaap	Interest Paid Net InterestPaidNet	36000	usd
CY2022	us-gaap	Interest Paid Net InterestPaidNet	340000	usd
CY2023	us-gaap	Prior Period Reclassification Adjustment Description PriorPeriodReclassificationAdjustmentDescription	<p id="xdx_849_eus-gaap--PriorPeriodReclassificationAdjustmentDescription_zfonbGP5A5c2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86F_zRJluZAp4up3">Reclassifications</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certain prior period amounts have been reclassified to conform to the current period presentation. These reclassifications had no effect on the reported results of operations.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2023	us-gaap	Use Of Estimates UseOfEstimates	<p id="xdx_844_eus-gaap--UseOfEstimates_zGLnvEBDjHCh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_863_zuENd8gbPw54">Use of Estimates</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of financial statements in conformity with generally accepted accounting principles in the United States (“U.S. GAAP”) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses for the reporting period. Actual results could significantly differ from those estimates. On an ongoing basis, the Company evaluates its significant estimates and assumptions including expense recognition and accrual assumptions under consulting and clinical trial agreements, stock-based compensation, impairment assessments, accounting for licensed rights to use technologies and other long-lived assets, contingency recognition and accruals and the determination of valuation allowance requirements on deferred tax attributes.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2023	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-33000000.0	usd
CY2023Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-179500000	usd
CY2023Q1	XAIR	Cash And Cash Equivalents And Marketable Securities CashAndCashEquivalentsAndMarketableSecurities	45900000	usd
CY2023Q1	us-gaap	Restricted Cash RestrictedCash	7400000	usd
CY2022Q1	us-gaap	Restricted Cash RestrictedCash	7400000	usd
CY2023Q1	us-gaap	Restricted Cash RestrictedCash	7400000	usd
CY2023Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	29158000	usd
CY2022Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	80242000	usd
CY2023Q1	us-gaap	Restricted Cash Current RestrictedCashCurrent	10129000	usd
CY2022Q1	us-gaap	Restricted Cash Current RestrictedCashCurrent	9988000	usd
CY2023Q1	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	39287000	usd
CY2022Q1	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	90230000	usd
CY2023Q1	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	16724000	usd
CY2023Q1	us-gaap	Cash Cash Equivalents And Short Term Investments CashCashEquivalentsAndShortTermInvestments	56011000	usd
CY2022Q1	us-gaap	Cash Cash Equivalents And Short Term Investments CashCashEquivalentsAndShortTermInvestments	90230000	usd
CY2023Q1	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	16724000	usd
CY2023	XAIR	Marketable Securities Current Unrealized Loss MarketableSecuritiesCurrentUnrealizedLoss	12000	usd
CY2023Q1	us-gaap	Marketable Securities Noncurrent MarketableSecuritiesNoncurrent	0	usd
CY2023Q1	us-gaap	Accumulated Other Comprehensive Income Loss Foreign Currency Translation Adjustment Net Of Tax AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax	43000	usd
CY2023Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Five FiniteLivedIntangibleAssetsAmortizationExpenseYearFive	205000	usd
CY2023Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense After Year Five FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive	607000	usd
CY2023Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	205000	usd
CY2023Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	205000	usd
CY2023Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	205000	usd
CY2023Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	205000	usd
CY2023Q1	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	1632000	usd
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod	202600	shares
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue	6.32
CY2023Q1	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	6256000	usd
CY2022Q1	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	2762000	usd
CY2023Q1	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	1254000	usd
CY2022Q1	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	767000	usd
CY2023Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	5003000	usd
CY2022Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1995000	usd
CY2023	us-gaap	Depreciation And Amortization DepreciationAndAmortization	634000	usd
CY2022	us-gaap	Depreciation And Amortization DepreciationAndAmortization	314000	usd
CY2021Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber	554200	shares
CY2021Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue	5.07
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod	615000	shares
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	8.37
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod	17000	shares
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeitures Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue	5.23
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber	949600	shares
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue	6.92
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod	434500	shares
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	6.27
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod	274600	shares
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue	6.50
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod	8400	shares
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeitures Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue	5.06
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber	1101100	shares
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue	6.78
CY2023	us-gaap	Employee Benefits And Share Based Compensation EmployeeBenefitsAndShareBasedCompensation	2400000	usd
CY2022	us-gaap	Employee Benefits And Share Based Compensation EmployeeBenefitsAndShareBasedCompensation	1700000	usd
CY2021Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	4195097	shares
CY2021Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	4.91
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P8Y4M24D
CY2021Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	2609000	usd
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	1673500	shares
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	7.14
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercised ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised	259904	shares
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	4.97
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	100062	shares
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	5.11
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	5508631	shares
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	5.60
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P8Y1M6D
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	6831000	usd
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	2805500	shares
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	6.32
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercised ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised	15000	shares
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	5.21
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	100250	shares
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	6.38
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	8198881	shares
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	5.83
CY2023	XAIR	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm1	P8Y4M24D
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	8306000	usd
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	3481943	shares
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	5.85
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P6Y4M24D
CY2023Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	6110000	usd
CY2023Q1	XAIR	Total Shortterm Accrued Expense TotalShorttermAccruedExpense	16613000	usd
CY2022Q1	XAIR	Total Shortterm Accrued Expense TotalShorttermAccruedExpense	8374000	usd
CY2023Q1	XAIR	Circassia Settlement Longterm CircassiaSettlementLongterm	4500000	usd
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y3M
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y3M
CY2023	us-gaap	Share Based Compensation ShareBasedCompensation	19558000	usd
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	7831000	usd
CY2023Q1	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	460520	shares
CY2023Q1	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	6.08
CY2023Q1	XAIR	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 Intrinsic Value ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1IntrinsicValue	406	usd
CY2022	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	6000000.0	usd
CY2022Q1	XAIR	Circassia Settlement Longterm CircassiaSettlementLongterm	8000000	usd
CY2023Q1	us-gaap	Other Long Term Debt OtherLongTermDebt	4500000	usd
CY2022Q1	us-gaap	Other Long Term Debt OtherLongTermDebt	8000000	usd
CY2023Q1	XAIR	Operating Lease Right Of Use Asset Current OperatingLeaseRightOfUseAssetCurrent	609000	usd
CY2023Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1850000	usd
CY2022Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	2044000	usd
CY2023Q1	XAIR	Vendors Research And Development VendorsResearchAndDevelopment	426000	usd
CY2022Q1	XAIR	Vendors Research And Development VendorsResearchAndDevelopment	1006000	usd
CY2023Q1	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	1221000	usd
CY2022Q1	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	442000	usd
CY2023Q1	us-gaap	Accrued Employee Benefits Current AccruedEmployeeBenefitsCurrent	985000	usd
CY2022Q1	us-gaap	Accrued Employee Benefits Current AccruedEmployeeBenefitsCurrent	409000	usd
CY2023Q1	XAIR	Contingent Litigation And Settlements ContingentLitigationAndSettlements	10298000	usd
CY2022Q1	XAIR	Contingent Litigation And Settlements ContingentLitigationAndSettlements	2435000	usd
CY2023Q1	XAIR	Circassia Settlement Current CircassiaSettlementCurrent	3500000	usd
CY2022Q1	XAIR	Circassia Settlement Current CircassiaSettlementCurrent	2500000	usd
CY2022Q1	XAIR	Nitricgen Agreement NitricgenAgreement	1500000	usd
CY2023Q1	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	184000	usd
CY2022Q1	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	82000	usd
CY2023Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	2493000	usd
CY2022Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	2216000	usd
CY2023Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	376000	usd
CY2022Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	281000	usd
CY2023Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	2321000	usd
CY2022Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	2079000	usd
CY2023Q1	us-gaap	Operating Lease Liability OperatingLeaseLiability	2697000	usd
CY2022Q1	us-gaap	Operating Lease Liability OperatingLeaseLiability	2361000	usd
CY2023	us-gaap	Operating Lease Payments OperatingLeasePayments	500000	usd
CY2023Q1	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P6Y6M
CY2023Q1	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.085	pure
CY2023Q1	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	582000	usd
CY2023Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	593000	usd
CY2023Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	551000	usd
CY2023Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	452000	usd
CY2023Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFive	404000	usd
CY2023Q1	us-gaap	Lessee Operating Lease Liability Payments Due After Year Five LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive	916000	usd
CY2023Q1	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	3497000	usd
CY2023Q1	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	800000	usd
CY2023Q1	us-gaap	Operating Lease Liability OperatingLeaseLiability	2697000	usd
CY2023	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	9760501	shares
CY2022	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	6918751	shares
CY2022Q3	XAIR	Loss Contingency Accrual Payment Liabilities LossContingencyAccrualPaymentLiabilities	2500000	usd
CY2023Q1	XAIR	Loss Contingency Accrual Payment Liabilities LossContingencyAccrualPaymentLiabilities	8000000.0	usd
CY2023Q1	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Two LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo	80000	usd
CY2023Q1	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Three LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree	120000	usd
CY2023Q1	us-gaap	Long Term Debt LongTermDebt	200000	usd
CY2023Q1	us-gaap	Loans Payable LoansPayable	695000	usd
CY2022Q1	us-gaap	Loans Payable LoansPayable	927000	usd
CY2023	us-gaap	Debt Instrument Periodic Payment DebtInstrumentPeriodicPayment	88000	usd
CY2022	us-gaap	Debt Instrument Periodic Payment DebtInstrumentPeriodicPayment	104000	usd
CY2023	XAIR	Number Of Payments NumberOfPayments	8
CY2022	XAIR	Number Of Payments NumberOfPayments	10
CY2023Q1	us-gaap	Debt Instrument Interest Rate Stated Percentage DebtInstrumentInterestRateStatedPercentage	0.0485	pure
CY2022Q1	us-gaap	Debt Instrument Interest Rate Stated Percentage DebtInstrumentInterestRateStatedPercentage	0.013	pure
CY2023	XAIR	Loan Payable Due Date Description LoanPayableDueDateDescription	November 2023
CY2022	XAIR	Loan Payable Due Date Description LoanPayableDueDateDescription	December 2022
CY2023Q1	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	1400000	usd
CY2023	XAIR	Operating Loss Carryforwards Expiration Years OperatingLossCarryforwardsExpirationYears	March 2018 expire through 2037
CY2023Q1	us-gaap	Deferred Tax Liabilities Deferred Expense Capitalized Research And Development Costs DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts	8000000.0	usd
CY2023	us-gaap	Operating Loss Carryforwards Limitations On Use OperatingLossCarryforwardsLimitationsOnUse	This limitation would generally apply in the event of a cumulative change in ownership of the Company of more than 50% within a three-year period
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-49720000	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-39148000	usd
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	-9681000	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	-4912000	usd
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-59401000	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-44060000	usd
CY2023Q1	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	28240000	usd
CY2022Q1	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	22952000	usd
CY2023Q1	us-gaap	Deferred Tax Assets In Process Research And Development DeferredTaxAssetsInProcessResearchAndDevelopment	1624000	usd
CY2022Q1	us-gaap	Deferred Tax Assets In Process Research And Development DeferredTaxAssetsInProcessResearchAndDevelopment	1226000	usd
CY2023Q1	XAIR	Research And Development Tax Credit Capitalization ResearchAndDevelopmentTaxCreditCapitalization	2158000	usd
CY2023Q1	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	23000	usd
CY2022Q1	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	-162000	usd
CY2023Q1	XAIR	Deferred Tax Assets Tax Deferred Expense Compensation And Depreciation DeferredTaxAssetsTaxDeferredExpenseCompensationAndDepreciation	-1228000	usd
CY2023Q1	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	6731000	usd
CY2022Q1	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	3268000	usd
CY2023Q1	XAIR	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Capital Loss Carryforward DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCapitalLossCarryforward	1559000	usd
CY2022Q1	XAIR	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Capital Loss Carryforward DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCapitalLossCarryforward	1559000	usd
CY2023Q1	XAIR	Deferred Tax Assets Reserves And Accruels DeferredTaxAssetsReservesAndAccruels	5291000	usd
CY2022Q1	XAIR	Deferred Tax Assets Reserves And Accruels DeferredTaxAssetsReservesAndAccruels	3580000	usd
CY2023Q1	XAIR	Deferred Tax Assets Rightofuse Asset DeferredTaxAssetsRightofuseAsset	-484000	usd
CY2022Q1	XAIR	Deferred Tax Assets Rightofuse Asset DeferredTaxAssetsRightofuseAsset	-464000	usd
CY2023Q1	XAIR	Deferred Tax Assets Lease Liability DeferredTaxAssetsLeaseLiability	524000	usd
CY2022Q1	XAIR	Deferred Tax Assets Lease Liability DeferredTaxAssetsLeaseLiability	495000	usd
CY2023Q1	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	44438000	usd
CY2022Q1	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	32454000	usd
CY2023Q1	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	44438000	usd
CY2022Q1	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	32454000	usd
CY2023	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21	pure
CY2023	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.2100	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.2100	pure
CY2023	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	-0.0435	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	-0.0621	pure
CY2023	XAIR	Effective Income Tax Rate Reconciliation Permanent Items EffectiveIncomeTaxRateReconciliationPermanentItems	0.0008	pure
CY2022	XAIR	Effective Income Tax Rate Reconciliation Permanent Items EffectiveIncomeTaxRateReconciliationPermanentItems	-0.0086	pure
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	0.2017	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	0.2931	pure
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Research And Development EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment	-0.0067	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Research And Development EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment	-0.0065	pure
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential	0.0281	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential	0.0000	pure
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	0.0296	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	-0.0059	pure
CY2023	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.0000	pure
CY2022	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.0000	pure
CY2023	XAIR	Collateral Amount CollateralAmount	7400000	usd
CY2023Q1	us-gaap	Loss Contingency Accrual At Carrying Value LossContingencyAccrualAtCarryingValue	7600000	usd
CY2022	us-gaap	Legal Fees LegalFees	4000	usd

Files In Submission

Name	View Source	Status
0001493152-23-022150-index-headers.html	Edgar Link	pending
0001493152-23-022150-index.html	Edgar Link	pending
0001493152-23-022150.txt	Edgar Link	pending
0001493152-23-022150-xbrl.zip	Edgar Link	pending
ex10-29.htm	Edgar Link	pending
ex21-1.htm	Edgar Link	pending
ex23-1.htm	Edgar Link	pending
ex23-2.htm	Edgar Link	pending
ex31-1.htm	Edgar Link	pending
ex31-2.htm	Edgar Link	pending
ex32-1.htm	Edgar Link	pending
ex32-2.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
form10-k.htm	Edgar Link	pending
form10-k_001.jpg	Edgar Link	pending
form10-k_002.jpg	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
form10-k_htm.xml	Edgar Link	completed
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
xair-20230331.xsd	Edgar Link	pending
xair-20230331_cal.xml	Edgar Link	unprocessable
xair-20230331_def.xml	Edgar Link	unprocessable
xair-20230331_lab.xml	Edgar Link	unprocessable
xair-20230331_pre.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$XAIR
Beyond Air, Inc. Stock $xair

2023 Q2 Form 10-K Financial Statement

#000149315223022150 Filed on June 22, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$XAIR Beyond Air, Inc. Stock $xair

2023 Q2 Form 10-K Financial Statement

#000149315223022150 Filed on June 22, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$XAIR
Beyond Air, Inc. Stock $xair